Overview

The Effect Of Fesoterodine On Pharmacokinetics And Pharmacodynamics Of Warfarin In Healthy Subjects

Status:
Completed
Trial end date:
2009-08-01
Target enrollment:
Participant gender:
Summary
This is an open-label, randomized, two-way crossover study to evaluate the steady-state effect of fesoterodine (8 mg QD) on the pharmacodynamics and pharmacokinetics of a single supratherapeutic dose of warfarin (25 mg) in healthy subjects.
Phase:
Phase 1
Details
Lead Sponsor:
Pfizer
Treatments:
Fesoterodine
Warfarin